Xcellerex

Xcellerex, now a brand within Cytiva, pioneered single-use technologies for biopharmaceutical manufacturing. Founded in 2002 by Parrish Galliher, the company was established to provide a more efficient alternative to traditional stainless-steel manufacturing systems. Galliher's initial prototype for a disposable single bioreactor, ingeniously fashioned from a backyard grill, led to the development of the Xcellerex brand and its product line. Prior to its acquisition, the company had raised approximately $59.5 million from investors including Kleiner Perkins, SCG Capital, and VantagePoint Venture Partners.

In March 2012, GE Healthcare announced its acquisition of Xcellerex, a move designed to broaden its portfolio of products and services for the biopharmaceutical manufacturing industry. This acquisition integrated Xcellerex's flexible, single-use systems with GE Healthcare's capabilities in upstream and downstream bioprocessing. Xcellerex operates as a key product platform within Cytiva, which is the life sciences division of the Danaher Corporation, following Danaher's acquisition of GE Healthcare's Life Sciences business.

The company's core offering is centered on the Xcellerex™ platform, which includes single-use stirred-tank bioreactors (XDR), mixers (XDM), and the FlexFactory®, a modular and portable production platform. These products are designed to offer faster installation, lower capital investment, reduced risk of cross-contamination, and increased flexibility compared to conventional technologies. The XDR bioreactors are scalable from 10L up to 2000L, supporting processes from development to cGMP production. The business serves the biopharmaceutical industry, enabling the manufacture of vaccines, monoclonal antibodies, and recombinant proteins.

Keywords: single-use bioreactors, biopharmaceutical manufacturing, FlexFactory, Cytiva, bioprocessing, stirred-tank bioreactors, monoclonal antibodies, vaccine production, perfusion systems, process development, modular manufacturing, cell culture technology, upstream bioprocessing, downstream bioprocessing, single-use technology, recombinant proteins, cGMP manufacturing, life sciences, gene therapy, biopharma.